The clinical activity of the MDM2 inhibitor RG7112 was assessed in a phase I trial in which RG7112 was administered to 20 patients with heavily pretreated CLL, of whom 6 had TP53 defects [82]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.